Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649894 | 0.97 | PRKAA2 (0.54) | PRKAA2HRH3ACHEPRKAB2PRKAG1 | |
| SCHEMBL649405 | 0.92 | HRH3 (0.58) | PRKAA2HRH3ACHEPRKAB2PRKAG1 | |
| SCHEMBL648581 | 0.89 | PRKAA2 (0.54) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL4449531 | 0.88 | ACHE (0.58) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4405711 | 0.85 | ACHE (0.52) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL648725 | 0.85 | CHRM4 (0.60) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL649755 | 0.85 | SLC6A5 (0.54) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10126949 | 0.85 | PRKAA2 (0.53) | PRKAA2HRH3ACHEPRKAB2PRKAG1 | |
| SCHEMBL16356172 | 0.85 | MAOA (0.57) | PRKAA2HRH3ACHEPRKAB2PRKAG1 | |
| SCHEMBL15171670 | 0.85 | PRKAA2 (0.59) | PRKAA2HRH3ACHEPRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174964-B2 | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2231600-B1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569340-B2 | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | PRKAA2 2/4885HRH3 3485/4885ACHE 1963/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | PRKAA2 2/4885HRH3 3485/4885ACHE 1963/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | PRKAA2 3/4885HRH3 1885/4885ACHE 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.